Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Follicum AB"},{"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Affibody"},{"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All patients included in Follicum\u2019s Phase II Study with FOL-005 for Stimulation of Hair Growth","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Follicum AB"},{"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum AB Reports that All Patients Have Completed Treatment With FOL-005 in the Phase II Study Against Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Follicum AB"},{"company":"Promore Pharma","sponsor":"Pergamum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Recruited to Promore Pharma's Clinical Trial Regarding Scarring According to Plan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Promore Pharma"}]

Promore Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

First Patient Recruited to Promore Pharma's Clinical Trial Regarding Scarring According to Plan

Details:

The company's ensereptide program is focused on the prevention of skin scarring in conjunction with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of tissue adhesions after hand and spine surgery.

Lead Product(s): Ensereptide

Therapeutic Area: Dermatology Product Name: PXL01

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Pergamum AB

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2022

ASK
US

Upload
your Pipeline Activity

Follicum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Follicum AB Reports that All Patients Have Completed Treatment With FOL-005 in the Phase II Study Against Hair Loss

Details:

FOL-005 is a modified, short version of the endogenous protein, osteopontin. The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation.

Lead Product(s): FOL-005

Therapeutic Area: Dermatology Product Name: FOL-005

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2021

ASK
US

Upload
your Pipeline Activity

Follicum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

All patients included in Follicum’s Phase II Study with FOL-005 for Stimulation of Hair Growth

Details:

The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. Patients themselves apply one of three different strengths of FOL-005 or placebo to the scalp once a day.

Lead Product(s): FOL-005

Therapeutic Area: Dermatology Product Name: FOL-005

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 08, 2020

ASK
US

Upload
your Pipeline Activity

Affibody

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

Details:

The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include further indications.

Lead Product(s): ABY-035

Therapeutic Area: Dermatology Product Name: ABY-035

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

ASK
US

Upload
your Pipeline Activity

Follicum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres

Details:

In two previous clinical studies, FOL-005 administered as an intradermal injection has been shown to be an effective and safe treatment for stimulation of hair growth.

Lead Product(s): FOL-005

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY